Chinook Therapeutics, Inc.
108 articles about Chinook Therapeutics, Inc.
-
Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering
11/10/2021
Chinook Therapeutics, Inc. announced the pricing of its upsized underwritten public offering of 7,828,572 shares of its common stock at a price to the public of $14.00 per share.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
11/8/2021
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2021.
-
Chinook Therapeutics Announces Proposed Public Offering of Common Stock - Nov 08, 2021
11/8/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that it intends to offer and sell 6,000,000 shares of its common stock in an underwritten public offering.
-
Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021
11/4/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced six ePoster presentations on the BION-1301 and atrasentan clinical programs at ASN Kidney Week 2021.
-
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2021
10/15/2021
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at ASN Kidney Week 2021 from November 4-7, 2021.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - Sep 20, 2021
9/20/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences in September 2021
9/2/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences.
-
Toronto saw the biggest growth in technology jobs of any North American city between 2015 and 2020, while Vancouver, British Columbia also made the top five.
-
Chinook Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
8/12/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, provided a business update and reported financial results for the second quarter ended June 30, 2021.
-
Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2021
7/12/2021
Chinook Therapeutics, Inc. today announced that Chinook management is scheduled to participate in a virtual fireside chat at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 12:00 pm ET.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 07, 2021
7/7/2021
Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase 25,733 shares of common stock with a grant date of June 30, 2021 for a new employee.
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
Chinook Therapeutics Announces Promotions of Tom Frohlich to Chief Operating Officer and Andrew King, D.V.M, Ph.D., to Chief Scientific Officer
6/9/2021
Chinook Therapeutics, Inc. (Nasdaq: KDNY), today announced that Tom Frohlich, chief business officer, has been promoted to chief operating officer (COO) of Chinook and Andrew King, D.V.M, Ph.D., head of renal discovery and translational medicine, has been promoted to chief scientific officer (CSO) of Chinook
-
Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress
6/8/2021
Chinook Therapeutics today announced the presentation of data from the ongoing phase 1/2 study of BION-1301 in patients with IgAN.
-
Chinook Therapeutics to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 58th ERA-EDTA Congress
5/25/2021
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the company will host a live conference call and webcast on Tuesday, June 8, 2021 at 1:00 pm PDT to discuss the interim data from Part 3 of Chinook’s ongoing phase 1b study of BION-1301 in patients with IgA nephropathy that will be presented at the 58th ERA-EDTA Congress.
-
Chinook Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference
5/13/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55 am ET.
-
Chinook Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
5/12/2021
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2021.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2021
5/4/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 125,267 shares of common stock with a grant date of April 30, 2021 for two new employees.
-
Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021
4/15/2021
Poster presentation on BION-1301 including Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and 2 of the ongoing phase 1b study of BION-1301 and data from the phase 1 IV to SC bioavailability study in healthy volunteers Poster presentation on atrasentan’s effect to rapidly reduce albuminuria and downregulate intra-renal transcriptional proliferative, inflammatory and fibrotic signaling in the gddY mouse IgAN model